10 December 2014
EMA/PDCO/697054/2014
Procedure Management and Business Support Division

Paediatric Committee (PDCO)

Minutes of the 12-14 November 2014 meeting

Chair: Dirk Mentzer - Vice-chair: Koenraad Norga

Disclaimers

Some of the information contained in the PDCO minutes is considered commercially confidential or sensitive and therefore not disclosed in the present minutes. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. The procedures discussed by the PDCO are on-going and therefore certain aspects of them are considered confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued). Documents mentioned in these minutes cannot be released at present as they are currently in draft format or are classified as confidential. They will become public when adopted in their final form or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

I Introduction

I.1 Adoption of the minutes from previous meeting

The Minutes of the PDCO plenary session held on 8 - 10 October 2014 were adopted.

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.2 Adoption of the Agenda

The agenda was adopted with amendments.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.3 Declaration of Conflict of Interest

See Annex I

I.4 External attendance

Please refer to the November 2014 PDCO monthly report published on the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

I.5 Leaving/New Members and Alternates

Please refer to the November 2014 PDCO monthly report published on the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

II Opinions

II.1 Opinions on Products

II.2 Opinions on Compliance Check

II.3 Opinions on Modification of an Agreed Paediatric Investigation Plan

Please refer to the November 2014 PDCO monthly report published in the EMA Website:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab

III Discussion of applications

The PDCO discussed n. 91 procedures in total[1], of which:

- 32 paediatric investigation plan applications;
- 12 product-specific waiver applications;
- 12 compliance check procedures (interim and final);
- 35 requests for modifications of an agreed paediatric investigation plan.

IV Nomination

IV.1 Nomination of Rapporteurs and Peer reviewers

• List of letters of intent received for submission of applications with start of procedure January 2015[1] for Nomination of Rapporteur and Peer reviewer • Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver	The PDCO approved the lists of Rapporteurs and Peer Reviewers.

IV.2 Nomination for other activities

V Update and finalisation of opinions and requests for modification

The opinions adopted during the Paediatric Committee meeting of November 2014 are published in the same month's meeting report published in the EMA website: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/document_listing/document_listing_000192.jsp&mid=WC0b01ac0580028eab.

VI Discussion on the applicability of class waiver

Active substance	Proposed indication	Condition	Outcome	Potential paediatric interest of this medicine suggested by PDCO
Veliparib	Treatment of brain metastases from Non-Small Lung Cancer (NSCLC) in combination with whole brain radiation therapy (WBRT).	Treatment of lung carcinoma (small cell and non-small cell carcinoma)	Positive	Paediatric malignancies characterized by DNA repair defects or in which DNA repair deficiency can be induced.

[1] The procedures discussed by the PDCO are on-going and therefore are considered confidential. Additional details on these procedures will be disclosed in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Taselisib	Treatment of non-small cell lung cancer (NSCLC).	Treatment of lung carcinoma (small cell and non-small cell carcinoma)	Positive	Paediatric malignancies with upregulated class 1 phosphoinositide 3-kinase (PI3K) alpha due to loss of suppressor genes or with mutated PI3K.

VII Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

No requests were made for the month of November.

VIII Annual reports on deferrals

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
EMEA-000567-PIP01-09	Dasatinib	Sprycel	Yes	No	The PDCO noted the report.
EMEA-000431-PIP01-08	triphenylacetic acid - 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)	Relvar Ellipta	No	No	The PDCO noted the report.
EMEA-000968-PIP02-11	elvitegravir	Vitekta	No	No	The PDCO noted the report.
EMEA-000599-PIP01-09	Influenza virus surface antigens (haemagglutinin and neuraminidase)* of H5N1	Focetria and associated names, Aflunov and associated names	No	Yes	The PDCO noted the report. A request for modification is planned for 2015.
EMEA-000689-PIP01-09	exenatide	Byetta	No	Yes	The PDCO noted the report. A request for modification is being initiated to rectify the issue.
EMEA-000430-PIP01-08-M04	rivaroxaban	Xarelto	No	No	The PDCO noted the report.

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
EMEA-000290-PIP01-08	nilotinib	Tasigna	Yes	No	The PDCO noted the report.
EMEA-000452-PIP02-10	Tadalafil	Cialis, Adcirca	No	No	The PDCO noted the report.
EMEA-000694-PIP01-09	dapagliflozin	Forxiga	No	No	The PDCO noted the report.
EMEA-000468-PIP02-12	posaconazole	Noxafil	No	Yes	The PDCO was informed of the delay of the PIP due to the need for development of an alternative age-appropriate oral formulation. The applicant has already submitted a request for modification of the agreed PIP.
EMEA-000205-PIP01-08	ceftobiprole medocaril sodium	Zeftera	No	No	The PDCO noted the report.
EMEA-000205-PIP02-11	ceftobiprole medocaril sodium	Zevtera	No	No	The PDCO noted the report.
EMEA-000160-PIP01-07	purified antigen fractions of inactivated split virion Influenza A/Vietnam/1194/...	Pandemrix, Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) (referring to Informed Consent for Prepandrix), Prepandrix	No	No	Duplicate of the annual report submitted in August 2014. Plan progressing according to agreed PIP.

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
EMEA-000317-PIP01-08	rilpivirine	Edurant	No	No	The PDCO noted the report. A modification of the initiation date for study 4 is currently under PDCO review.
EMEA-000980-PIP01-10	brentuximab vedotin	Adcetris	Yes	Yes	The PDCO noted the report.
EMEA-001030-PIP01-10	canagliflozin	Invokana	No	Yes	The PDCO was informed on the difficulties in progressing the PIP by the applicant and the recruitment challenges encountered for the clinical studies. The applicant has subsequently submitted a request for a modification of the agreed PIP .
EMEA-001318-PIP01-12	zanamivir	Relenza	No	Yes	The PDCO noted the report. A request for modification is planned for 2015.
EMEA-000035-PIP02-09	tiotropium bromide (monohydrate)	Spiriva Respimat 2.5 microgram, solution for inhalation, Spiriva 18	No	Yes	The PDCO was informed of the delay of the PIP due to slower than

Annual report based on PIP decision for	Substances (abbrev.)	Product Name	Orphan	Difficulties progressing the PIP?	Outcome
		microgram, inhalation powder, hard capsule			expected recruitment into the paediatric trials. The applicant has already submitted a request for modification of the agreed PIP.
EMEA-000367-PIP01-08	human recombinant C1 inhibitor	Rhucin	Yes	Yes	The PDCO noted the report. The PIP is expected to be completed in 2015.
EMEA-001149-PIP01-11	human Fibrinogen / Human Thrombin	Evarrest, Evicel	No	Yes	The PDCO was informed of a delay of the PIP due to operational problems in the development of a smaller size medicated sponge. The applicant plans to submit a request for modification of the agreed PIP in early 2015.
EMEA-000410-PIP01-08	regadenoson	Rapiscan	No	No	The PDCO noted the report.

IX Other topics

Guidelines	
Paediatric addendum to the NfG on HTN	The 'Paediatric addendum to the note for guidance on the clinical investigation on medicinal products in the treatment of hypertension' was presented to the committee with some minor changes from PDCO members received prior to the plenary meeting. The addendum was endorsed.
Working groups	
Paediatric inventory	No meeting was held in the current month.
Paediatric oncology	No meeting was held in the current month.
Extrapolation	No meeting was held in the current month.
Formulation	No non-product related issues were reported to the Committee.
Non-Clinical	No non-product related issues were reported to the Committee.
Neonatology	The neonatal group discussed mainly topics in the area of the neonatal guideline and ongoing initiatives in the field.
D30 Products identified for the Non-Clinical Working Group Jacqueline Carleer	Documents tabled for information.
PDCO Improvement exercise – second brainstorming session	Due to time constraints, the working group meeting was postponed to December 2014.
Product-related topics	
Signal of cardiovascular events with sodium containing effervescent, dispersible and soluble medicines: Responses to the PRAC questions Angeliki Siapkara	The safety signal was presented to the PDCO as well as the PRAC request for PDCO advice regarding the threshold and improvement of labelling for sodium containing medicines used in children. PDCO members were asked to provide written comments so that a global

	response can be compiled and presented for endorsement at next PDCO plenary meeting.
Art.31 referral on Codeine to PRAC: PRAC request for PDCO advice	An introductory presentation on the Codeine referral and PRAC request for PDCO advice was given to the PDCO members.
CHMP update on paediatric topics	The PDCO members were informed about the CHMP opinions on one medicinal product with paediatric indication adopted in October 2014.
CHMP discussion on paediatric type 2 diabetes Agnes Gyurasics	The Committee was informed on general discussion at CHMP on the approach to extrapolation used by PDCO for assessment of PIPs for products for treatment of type 2 diabetes. It was identified the need for follow-up discussions between representatives of both scientific Committees.
Joint session with the Formulation Working Group	The FWG shared a session with the PDCO plenary. Discussions took place on the work of the FWG and appreciation was expressed for the continued contribution of its members to the work of the PDCO.
Other topics	
Funding of paediatric trials (specifically for off-patent medicines) in children	A plenary discussion took place with external participants representing EFPIA/IMI, from EnprEMA (representing EnprEMA and FP7 project applicants) and the European Commission representative about future approaches to funding of paediatric clinical trials. Future activities will be planned.
Involvement of children in PDCO and patients in committee evaluations	PDCO members and alternates were asked to complete a questionnaire by 19 November 2014. The aim of this exercise was to collect their views on the following matters: • involvement of children, adolescents (and their parents/carers/legal representatives) in the PDCO activities; • how to strengthen the participation of members representing patients' organisations in the PDCO

	discussions. The outcome of the questionnaire and the next steps will be presented at the next EMA PCWP meeting with all patients' and consumers' organisations as well as during the next PDCO plenary meeting. Moreover, an overview of patients' involvement in EMA Scientific Committees was presented to the PDCO.
Draft Work plan for the European Medicines Agency Human Scientific Committees' Working Party with Healthcare Professionals' Organisations (HCPWP) 2015	The draft work plan for the EMA Human Scientific Committees' Working Party with Healthcare Professionals' Organisations (HCPWP) was presented to the PDCO and subsequently adopted.
Draft Work plan for the European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP)	The draft work plan for the EMA Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) was presented to the PDCO and subsequently adopted.
Update on Enpr-EMA activities	Postponed to next PDCO meeting.
Task Force on Registries	The cross-agency project on registries was presented to the committee. Also, a request for members to volunteer for a cross-committee working group was put forward.
Project on impact of juvenile animal studies (part on anti-cancer medicines)	Preliminary findings were presented and discussed. First feedback from other scientific groups at the Agency was reported. The project report is being drafted and information will be publicly available in 2015.
PDCO and CHMP - Parenteral nutrition in the paediatric population	A request from CMDh concerning the development of guidance for product development for paediatric parenteral nutrition (PN) was discussed. It was considered that there is sufficient scientific treatment guidance on PN published by Learned Societies which is closely interrelated with development of products in this area. It was underlined that PDCO can provide scientific support for any specific product and topic related issues.

PDCO work plan 2015 – update	Postponed to PDCO December 2014 meeting.

Any other business

None.

The Chair thanked all participants and closed the meeting.

Annex to the Minutes of the PDCO of October 2014

List of Participants and Documentation on Declaration of interest of members, alternates and experts

Based on the Declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of Committee members for the upcoming discussions.

In accordance with the Agency's revised Policy and Procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests).

No new or additional conflicts were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting.

PDCO Chair	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product / substance
Dirk Mentzer	Germany	Full involvement	

PDCO Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product / substance
Karl-Heinz Huemer	Austria	Full involvement	
Koenraad Norga	Belgium	Full involvement	
Violeta Iotova	Bulgaria	No participation in discussions, final deliberations and voting	EMEA-000128-PIP01-07-M06 EMEA-001517-PIP02-14 EMEA-000828-PIP01-09-M03 EMEA-001677-PIP01-14 EMEA-000498-PIP01-08-M04 EMEA-C-000412-PIP01-08-M01

PDCO Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Marina Dimov Di Giusti	Croatia	Full involvement	
Georgios Savva	Cyprus	Full involvement	
Jaroslav Sterba	Czech Republic	No participation in final deliberations and voting	EMEA-000468-PIP02-12-M01 EMEA-001397-PIP03-14
Marianne Orholm	Denmark	Full involvement	
Pirjo Laitinen-Parkkonen	Finland	Full involvement	
Sylvie Benchetrit	France	Full involvement	
Birka Lehmann	Germany	Full involvement	
Grigorios Melas	Greece	Full involvement	
Agnes Gyurasics	Hungary	Full involvement	
Gylfi Oskarsson	Iceland	Full involvement	
Brian Aylward	Ireland	Full involvement	
Paolo Rossi	Italy	Full involvement	
Dina Apele-Freimane	Latvia	Full involvement	
Carola de Beaufort	Luxembourg	Full involvement	
John Joseph Borg	Malta	Full involvement	
Hendrik van den Berg	Netherlands	Full involvement	
Siri Wang	Norway	Full involvement	
Marek Migdal	Poland	Full involvement	
Helena Fonseca	Portugal	Full involvement	
Stefan Grosek	Slovenia	Full involvement	
Fernando de Andrés Trelles	Spain	Full involvement	
Viveca Lena Odlind	Sweden	Full involvement	

PDCO Member	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Angeliki Siapkara	United Kingdom	Full involvement	

PDCO Alternate	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Christoph Male	Austria	No participation in final deliberations and voting	EMEA-001215-PIP01-11-M02
Jacqueline Carleer	Belgium	Full involvement	
Peter Szitanyi	Czech Republic	Full involvement	
Ann Marie Kaukonen	Finland	Full involvement	
Immanuel Barth	Germany	Full involvement	
Francesca Rocchi	Italy	Full involvement	
Herbert Lenicker	Malta	Full involvement	
Ine Skottheim Rusten	Norway	Full involvement	
Hugo Tavares	Portugal	Full involvement	
Nela Vilceanu	Romania	Full involvement Replacing PDCO member	
Maria Jesús Fernández Cortizo	Spain	Full involvement	
Ninna Gullberg	Sweden	Full involvement	
Martina Riegl	United Kingdom	Full involvement	

PDCO Representative of doctors' organisations	Role	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Antje Neubert	Member	Representative of doctors' organisations	Full involvement	
Paolo Paolucci	Alternate	Representative of doctors' organisations	Full involvement	
Johannes Taminiau	Member	Representative of doctors' organisations	Full involvement	
Doina Plesca	Alternate	Representative of doctors' organisations	No participation in discussions, final deliberations and voting	EMEA-000696-PIP02-10-M05 EMEA-001202-PIP02-13 EMEA-001613-PIP01-14 EMEA-000035-PIP02-09-M02 EMEA-001214-PIP01-11-M02
Riccardo Riccardi	Member	Representative of doctors' organisations	Full involvement	
Maria Grazia Valsecchi	Alternate	Representative of doctors' organisations	No participation in discussions, final deliberations and voting	EMEA-001656-PIP01-14

PDCO Representative of patients' organisations	Role	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/substance
Gunther Auerswald	Member	Representative of patients' organisations	No participation in discussions, final deliberations and voting	EMEA-001215-PIP01-11-M02 EMEA-000731-PIP01-09-M02

EUROPEAN COMMISSION	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited
	European Commission	Full Involvement TC only	
	European Commission	Full Involvement	

PDCO Expert	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited Product/substance
*Experts were only evaluated against the product they have been invited to talk about.			
Adriana Ceci	Enpr-EMA	n/a	
Hector Rojas	Enpr-EMA	n/a	
Mark Turner	Enpr-EMA	n/a	
Magda Chlebus	EFPIA	n/a	
Eva Blahutova	Slovakia	Full involvement	
Dominik Karres	United Kingdom	Full involvement	
Juliana Min	United Kingdom	Full involvement	
Claire Doe	United Kingdom	Full involvement	
Jane Woolley	United Kingdom	Full involvement	

PDCO Expert By phone	Country	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which the expert is invited Product/substance
*Experts were only evaluated against the product they have been invited to talk about.			
Shai Izraeli	Israel	Full involvement	
Eric Legius	Belgium	Full involvement	
Sabine Scherer	Germany	Full involvement	
Adrienn Horváth	Hungary	Full involvement	

Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting.